---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-258372"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-06-05T11:12:49+00:00"
generated_at: "2026-06-05T11:15:09.066251+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026

## Summary
- Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.
- Preliminary safety from 49 healthy volunteers (single doses up to 320 mg): no SAEs, DLTs, or discontinuations; all AEs mild-moderate and transient.
- Partner Mabworks to initiate Phase 2 dosing in IgAN patients in Q3 2026 in China.
- Company plans to advance CLYM116 into further clinical development based on data.

## SEC filing metadata
- accession: 0001193125-26-258372
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-06-05T11:12:49+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/0001193125-26-258372-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526258372/d132290d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-258372
- JSON: https://secwatch.observer/filing/0001193125-26-258372.json
- Plain text: https://secwatch.observer/filing/0001193125-26-258372.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.